Mya Symons
Mya Symons
- Messages
- 1,029
- Location
- Washington
Here they go again. Is this a new one or do we already have it somewhere?
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017592
Investigation into the Presence of and Serological Response to XMRV in CFS Patients
The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS. In addition, sera from our CFS patients were assayed for the presence of xenotropic virus envelope protein, as well as a serological response to it. The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK.
ArticleMetricsRelated ContentComments: 0.To add a note, highlight some text. Hide notes
Make a general comment
Jump to
Abstract
Introduction
Materials and Methods
Results
Discussion
Acknowledgments
Author Contributions
References
Otto Erlwein1, Mark J. Robinson1, Steve Kaye1, Gillian Wills1, Shozo Izui2, Simon Wessely3, Jonathan Weber1, Anthony Cleare3, David Collier4, Myra O. McClure1*
1 Jefferiss Research Trust Laboratories, Section of Infectious Diseases, Wright-Fleming Institute, Faculty of Medicine, Imperial College London, London, United Kingdom, 2 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland, 3 Department of Psychological Medicine, Institute of Psychiatry, King's College London, Camberwell, London, United Kingdom, 4 Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, United Kingdom
Abstract Top
The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS. In addition, sera from our CFS patients were assayed for the presence of xenotropic virus envelope protein, as well as a serological response to it. The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK.
Citation: Erlwein O, Robinson MJ, Kaye S, Wills G, Izui S, et al. (2011) Investigation into the Presence of and Serological Response to XMRV in CFS Patients. PLoS ONE 6(3): e17592. doi:10.1371/journal.pone.0017592
Editor: Kim Hasenkrug, National Institute of Allergy and Infectious Diseases, United States of America
Received: November 26, 2010; Accepted: January 26, 2011; Published: March 9, 2011
Copyright: 2011 Erlwein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the NIHR Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: m.mcclure@imperial.ac.uk
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0017592
Investigation into the Presence of and Serological Response to XMRV in CFS Patients
The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS. In addition, sera from our CFS patients were assayed for the presence of xenotropic virus envelope protein, as well as a serological response to it. The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK.
ArticleMetricsRelated ContentComments: 0.To add a note, highlight some text. Hide notes
Make a general comment
Jump to
Abstract
Introduction
Materials and Methods
Results
Discussion
Acknowledgments
Author Contributions
References
Otto Erlwein1, Mark J. Robinson1, Steve Kaye1, Gillian Wills1, Shozo Izui2, Simon Wessely3, Jonathan Weber1, Anthony Cleare3, David Collier4, Myra O. McClure1*
1 Jefferiss Research Trust Laboratories, Section of Infectious Diseases, Wright-Fleming Institute, Faculty of Medicine, Imperial College London, London, United Kingdom, 2 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland, 3 Department of Psychological Medicine, Institute of Psychiatry, King's College London, Camberwell, London, United Kingdom, 4 Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, United Kingdom
Abstract Top
The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS. In addition, sera from our CFS patients were assayed for the presence of xenotropic virus envelope protein, as well as a serological response to it. The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK.
Citation: Erlwein O, Robinson MJ, Kaye S, Wills G, Izui S, et al. (2011) Investigation into the Presence of and Serological Response to XMRV in CFS Patients. PLoS ONE 6(3): e17592. doi:10.1371/journal.pone.0017592
Editor: Kim Hasenkrug, National Institute of Allergy and Infectious Diseases, United States of America
Received: November 26, 2010; Accepted: January 26, 2011; Published: March 9, 2011
Copyright: 2011 Erlwein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the NIHR Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: m.mcclure@imperial.ac.uk